If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... There is a slight trend in this direction, but it's too early ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid tumours." It is paying $800 million to acquire all of Biotheus' issued share ...

BioNTech is investing in a promising space in oncology by acquiring Biotheus’ PD-L1 and VEGF bispecific antibody.

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...

Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months after a ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

Keytruda (pembrolizumab) is a brand-name solution for IV infusion prescribed to treat many types of cancer, including melanoma and lung cancer. As with other drugs, Keytruda can cause side effects ...